Shandong Science ›› 2020, Vol. 33 ›› Issue (1): 42-50.doi: 10.3976/j.issn.1002-4026.2020.01.007

• Pharmacology and Toxicology • Previous Articles     Next Articles

Advances in respiratory syncytial virus and its infection-related Toll-like receptors

DU Hai-tao1,2, SUN Tie-feng2, WANG Ping2,3*, AN Feng-tian4, HU Ya-nan1, LI Na1   

  1. 1. School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; 2. Shandong Academy of Chinese Medicine, Jinan 250014, China; 3. State Key Laboratory of Precision Measurement Technology and Instruments, Tianjin University , Tianjin 300072, China; 4. Pharmaceutical Department of Qingdao Municipal Hospital, Qingdao 266011, China
  • Received:2019-07-25 Published:2020-02-20 Online:2020-02-13

Abstract: Respiratory syncytial virus (RSV) is the leading cause of respiratory tract infections in infants. Toll-like receptors, one of the pattern recognition receptors involved in innate immunity, play an important role in the identification and eradication of RSVs. However, this is not adequately examined, which has limited the development of antiviral drugs and vaccines. In this study, we reviewed the studies on the immunologic process of RSV-related Toll-like receptors in recent years and described the shortcomings of the methods and tendencies of the current studies. This is intended to provide ideas and methods for the further studies on new anti-RSV drugs and their mechanisms.

Key words: respiratory syncytial virus, toll-like receptors, mechanism, anti-virus

CLC Number: 

  • R289

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits third parties to freely share (i.e., copy and redistribute the material in any medium or format) and adapt (i.e., remix, transform, or build upon the material) the articles published in this journal, provided that appropriate credit is given, a link to the license is provided, and any changes made are indicated. The material may not be used for commercial purposes. For details of the CC BY-NC 4.0 license, please visit: https://creativecommons.org/licenses/by-nc/4.0